Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05683808 · ClinicalTrials.gov registry record · Phase 2
Venous Thromboembolism Prevention in Outpatients With Glioma
A Phase 2 study of Glioblastoma and Venous Thromboembolism, sponsored by University of Vermont Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05683808 is a Phase 2 study of Glioblastoma and Venous Thromboembolism that is actively recruiting participants, run by University of Vermont Medical Center. The registered enrollment target is 40 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05683808, a Phase 2 study of Glioblastoma and Venous Thromboembolism, is actively recruiting participants, sponsored by University of Vermont Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
Conditions Studied
Interventions
- DRUG Apixaban
Study Locations (1)
Vermont
- University of Vermont Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-01-16 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05683808
The ClinicalTrials.gov registry entry for NCT05683808 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (63% lower). The listed sponsor is University of Vermont Medical Center, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Apixaban is the first listed.
NCT05683808 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.
Frequently Asked Questions
What is clinical trial NCT05683808 about?
NCT05683808 is a clinical study titled "Venous Thromboembolism Prevention in Outpatients With Glioma". This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
What is the current status of trial NCT05683808?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-01-16. Estimated completion is 2027-06-30.
What conditions does trial NCT05683808 study?
This clinical trial studies the following conditions: Glioblastoma, Venous Thromboembolism, Astrocytoma.
What interventions are being tested in trial NCT05683808?
The interventions under investigation include: Apixaban (DRUG).
Who is sponsoring clinical trial NCT05683808?
This trial is sponsored by University of Vermont Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05683808 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
-
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.